Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®
Berkeley Heights, New Jersey, March 19th, 2026
Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International that markets, distributes, and sells generic medicines in the United States, today announced the launch of Milnacipran HCl Tablets, the generic equivalent of Savella® by AbbVie, in the pain management category.
This launch reflects Breckenridge’s continued focus on ensuring broad and reliable access to essential therapies for chronic conditions, where stability of supply, product quality, and affordability can directly impact patient well-being and treatment continuity.
Milnacipran HCl Tablets are indicated for the management of fibromyalgia. Milnacipran HCl is a potent inhibitor of neuronal norepinephrine and serotonin reuptake; milnacipran inhibits norepinephrine uptake with approximately 3-fold higher potency in vitro than serotonin without directly affecting the uptake of dopamine or other neurotransmitters. Please visit www.breckenridgepharma.com for the full prescribing information including boxed warning, precautions, and adverse reactions.
The product is approved for use in adults and is available in 12.5 mg, 25 mg, 50 mg, and 100 mg strengths. Milnacipran HCl Tablets are not approved for use in pediatric patients. Milnacipran HCl Tablets will be manufactured by Breckenridge’s partner, Centaur Pharmaceuticals Pvt. Ltd., and primarily distributed through retail and mail order pharmacies.
Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, Inc., commented: “This launch further strengthens Breckenridge’s retail portfolio and underscores our commitment to delivering reliable, high-quality generic medicines. By prioritizing affordability and reliable access, Breckenridge supports patients in obtaining the medications they rely on every day.”
Dr. Smita Phal, Executive Director of Centaur Pharmaceuticals, commented: “Our long-standing partnership with Breckenridge continues to create meaningful value for patients and healthcare systems alike. The introduction of Milnacipran HCl Tablets reinforces our dedication to providing robust, highquality manufacturing capabilities that support broader access to essential medications in the U.S. market.”
About Centaur Pharmaceuticals:
Centaur Pharmaceuticals stands among India’s few fully integrated pharmaceutical companies, combining strengths in API manufacturing, finished formulations, clinical research, and contract development & manufacturing. With operations and partnerships across 120+ countries, Centaur has built enduring alliances with global pharmaceutical companies.
